98%
921
2 minutes
20
Ashwagandha (Withania somnifera) is a widely used herbal supplement with established adaptogenic and neuroprotective properties. Although generally considered safe, rare adverse neurological effects may occur. We present the case of a previously healthy adult male who developed acute-onset dystonia following the initiation of Ashwagandha supplementation. The patient exhibited sustained involuntary muscle contractions and abnormal posturing shortly after commencing the supplement. Extensive diagnostic evaluation failed to identify an alternative etiology. Discontinuation of Ashwagandha and initiation of symptomatic treatment led to the resolution of symptoms. This case underscores the importance of considering herbal supplements as potential contributors to neurological presentations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397830 | PMC |
http://dx.doi.org/10.7759/cureus.89104 | DOI Listing |
Cureus
July 2025
Internal Medicine, Mediclinic Welcare Hospital, Dubai, ARE.
Ashwagandha (Withania somnifera) is a widely used herbal supplement with established adaptogenic and neuroprotective properties. Although generally considered safe, rare adverse neurological effects may occur. We present the case of a previously healthy adult male who developed acute-onset dystonia following the initiation of Ashwagandha supplementation.
View Article and Find Full Text PDFCureus
May 2025
Nursing & Midwifery Research, Hamad Medical Corporation, Doha, QAT.
Non-ketotic hyperglycemic hemichorea-hemiballismus (NHH) is a rare but reversible movement disorder associated with poorly controlled diabetes mellitus. It is characterized by involuntary, non-suppressible choreiform, ballistic movements or several other involuntary movements (dystonia, tremors, etc), contralateral striatal hyperintensity on MRI, and hyperglycemia without ketosis. The exact pathophysiology remains unclear, but prompt glycemic control is essential for symptom resolution.
View Article and Find Full Text PDFLancet Neurol
March 2025
Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute, INSERM UMR1163, Université Paris Cité, Paris, France. Electronic address:
Background: Through the agnostic screening of patients with uncharacterised disease phenotypes for an upregulation of type I interferon (IFN) signalling, we identified a cohort of individuals heterozygous for mutations in PTPN1, encoding the protein-tyrosine phosphatase 1B (PTP1B). We aimed to describe the clinical phenotype and molecular and cellular pathology of this new disease.
Methods: In this case series, we identified patients and collected clinical and neuroradiological data through collaboration with paediatric neurology and clinical genetics colleagues across Europe (Czechia, France, Germany, Italy, Slovenia, and the UK) and Israel.